Page 21 - 73_04

VOL. 73 (4), 813-832, 2007 NUEVOS ASPECTOS BIOFARMACÉUTICOS...

BIBLIOGRAFÍA

(1) DOMB, A.J.; TABATA, Y.; RAVI KUMAR, M. N.V. Y FARBER, S. (2007) Nanoparticles
(2) for pharmaceutical applications. Ed.: American Scientific Publishers. Los
Angeles.
(3) CANCER NANOTECHNOLOGY PLAN: A STRATEGIC INITIATIVE TO TRANSFORM CLINICAL ON-
(4) COLOGY AND BASIC RESEARCH THROUGH THE DIRECT APPLICATION OF NANOTECHNOLOGY.
(5) (2004) U.S. Department of Health and Human Services. National Institutes
(6) of Health. Health National Cancer Institute.
(7) EUROPEAN TECHNOLOGY PLATFORM: NANOMEDICINE. cordis.europa.eu/nanotechno-
(8) logy/nanomedicine.htm.
EUROPEAN MEDICINES AGENCY (2006) Reflection paper on nanotechology-based
(9) medicinal products for human use.
(10) UCHEGBU, I.F. (2006) Pharmaceutical nanotechnology: polymeric vesicles for
drug and gene delivery. Expert Opin. Drug Deliv. 3 (5): 629-640.
(11) ZAMBONI, W.C. (2005) Liposomal, nanoparticles and conjugatd formulations
of anticancer agents. Clin. Cancer Res. 11 (23): 8230-8234.
(12) TORCHILIN, V.P. (2007) Micellar nanocarriers: Pharmaceutical perspectives:
(13) Pharm. Res. 24 (1): 1-16.
(14) HATAKEYAMA, H.; AKITA, H.; KOGURE, K.; OISHI, M.; NAGASAKI, Y.; KIHIRA, Y.;
(15) UENO, M.; KOBAYASHI, H.; KIKUCHI, H. AND HARASHIMA, H. (2007) Development
(16) of a ovel system gene delivery system for cancer therapy with a tumor-
specific cleavable PEG-lipid. Gene Therapy. 14: 68-77.
YIH, T.C. AND AL-FANDI, M. (2006) Engineered nanoparticles as precise drug
delivery systems. J. Cell. Biochem. 97: 1184-1190.
CHENG, J.; TEPLY, B.A.; SHERIFI, I.; SUNG, J.; LUTHER, G.; GU, F.X.; LEVY-NIS-
SENBAUM, E.; RADOVIS-MORENO, A.F.; LANGER, R. AND FAROKHZAD, O.C. (2007)
Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted
drug delivery. Biomaterials. 28: 869-876.
XION, X.B.; HUANG, Y.; LU, W.L.; ZHANG, X.; NAGAI, T. AND ZHANG, G. (2005)
Intracelular delivery of doxorubicine with RGD modified sterically stabilized
liposomes for an improved antitumor efficacy in vitro and in vivo. J. Pharm.
Sci. 4: 1782-1793.
FAROKHZAD, O.C. AND LANGER, R. (2006) Nanomedicine: developing smarter
therapeutic and diagnostic modalities. Adv. Drug Del. Rev. 58: 1456-1459.
NISHIYAMA, N. AND KATAOKA, K. (2006) Current state, achievements and future
prospects of polymeric micelles as nanocarriers for drug and gene delivery.
Pharmacol. & Therapeutics. 112: 630-648.
KABANOV, A.V. (2006) Polymer genomics: An insight into pharmacology and
toxicology of nanomedicines. Adv. Drug Del. Rev. 58: 1597-1621.
AKHTAR, S. AND BENTER, I. (2007) Toxicogenomics of non-viral drug delivery
systems for RNAi: Potential impact on siRNA-mediated gene silencing acti-
vity and specificity. Adv. Drug Deliv. Rev. 59: 165-182.
COUVREUR, P. AND VAUTHIER, C. (2006) Nanotechnology: Intelligent design to
treat complex disease. Pharm. Res. 23: 1417-1450.

831